The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary

Bing Wang1, Jianfei Yao2, Ruiqing Ma1

  • 1Department of Myxoma, Aerospace Center Hospital, Beijing, China.

Insights

This study reveals the unique genetic mutations in rare ovarian pseudomyxoma peritonei (PMP). Key factors like PTPRK mutations and clinical markers may predict patient survival in this rare cancer.

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Pseudomyxoma peritonei (PMP) is a rare condition with distinct pathological and genetic features.
  • Ovarian-originating PMP is extremely rare, with limited research on its clinical features and mutational landscape compared to appendix-originating PMP.

Purpose of the Study:

  • To characterize the somatic mutational landscape of PMP originating from the ovary.
  • To identify prognostic factors predicting survival in patients with ovarian PMP.

Main Methods:

  • Examined 830 PMP cases to identify 16 instances of ovarian origin.
  • Performed whole-exome sequencing (WES) on 12 formalin-fixed, paraffin-embedded (FFPE) tissue samples.
  • Analyzed patient follow-up data for survival outcomes.

Main Results:

  • Mutations in cancer driver genes (TP53, ATM, SETD2, ATRX, EP300, FGFR2, KRAS, NOCR1, RB1) were found in a subset of patients.
  • High mutational frequencies were observed in MUC16, BSN, PCNT, PPP2R5A, PRSS36, PTPRK, and SBF1 genes.
  • Affected pathways included PI3K-Akt signaling, HPV infection, cell skeleton, adhesion, and extracellular matrix.
  • The 5-year overall survival (OS) rate was 71.2%, with a median OS not reached.
  • PTPRK mutations, presurgical CA199 levels, completeness of cytoreduction (CCR), and peritoneal cancer index (PCI) were identified as potential survival predictors.

Conclusions:

  • The study elucidated the distinct mutational landscape of ovary-originating PMP.
  • Ovarian PMP exhibits unique genetic features differentiating it from appendix-originating PMP.
  • PTPRK mutations, CA199, CCR, and PCI show potential as prognostic biomarkers for ovarian PMP.

Related Concept Videos